These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18051426)

  • 41. Analysis of FK506-mediated protection in an organotypic model of spinal cord damage: heat shock protein 70 levels are modulated in microglial cells.
    Guzmán-Lenis MS; Vallejo C; Navarro X; Casas C
    Neuroscience; 2008 Jul; 155(1):104-13. PubMed ID: 18577426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of tacrolimus derivatives on immunosuppression.
    Choi D; Cho H
    Arch Pharm Res; 2009 Apr; 32(4):549-57. PubMed ID: 19407973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The EMIT Tacrolimus assay: development of application protocol for Roche Hitachi 902 analyzer].
    Yargui L; Berhoune A
    Ann Biol Clin (Paris); 2008; 66(6):657-64. PubMed ID: 19091665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response.
    Du S; Hiramatsu N; Hayakawa K; Kasai A; Okamura M; Huang T; Yao J; Takeda M; Araki I; Sawada N; Paton AW; Paton JC; Kitamura M
    J Immunol; 2009 Jun; 182(11):7201-11. PubMed ID: 19454717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T.
    Gerard M; Debyser Z; Desender L; Baert J; Brandt I; Baekelandt V; Engelborghs Y
    J Neurochem; 2008 Jul; 106(1):121-33. PubMed ID: 18346205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation.
    Giordano A; Romano S; Mallardo M; D'Angelillo A; Calì G; Corcione N; Ferraro P; Romano MF
    Cardiovasc Res; 2008 Aug; 79(3):519-26. PubMed ID: 18349138
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isolation and identification of a novel microorganism producing the immunosuppressant tacrolimus.
    Kim HS; Park YI
    J Biosci Bioeng; 2008 Apr; 105(4):418-21. PubMed ID: 18499061
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioactivity of folding intermediates studied by the recovery of enzymatic activity during refolding.
    Aumüller T; Fischer G
    J Mol Biol; 2008 Mar; 376(5):1478-92. PubMed ID: 18234226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-, mid-, and long-term effects of a polymer-free tacrolimus-eluting stent in a porcine coronary model.
    Prunotto M; Vignolini C; Lolli V; Black A; Gaggianesi S; Santarelli A; Galloni M
    J Biomed Mater Res A; 2009 Mar; 88(4):872-9. PubMed ID: 18360883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tacrolimus (FK506) causes disease aggravation in models for inherited peripheral myelinopathies.
    Ip CW; Kroner A; Kohl B; Wessig C; Martini R
    Neurobiol Dis; 2009 Feb; 33(2):207-12. PubMed ID: 19028581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells.
    Romano S; Mallardo M; Chiurazzi F; Bisogni R; D'Angelillo A; Liuzzi R; Compare G; Romano MF
    Haematologica; 2008 Jul; 93(7):1039-48. PubMed ID: 18492692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tacrolimus-related polyneuropathy: case report and review of the literature.
    De Weerdt A; Claeys KG; De Jonghe P; Ysebaert D; Chapelle T; Roeyen G; Jorens PG
    Clin Neurol Neurosurg; 2008 Mar; 110(3):291-4. PubMed ID: 18055100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty.
    Dhaliwal JS; Mason BF; Kaufman SC
    Cornea; 2008 May; 27(4):488-93. PubMed ID: 18434855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FK506-protective effects against trimethyltin neurotoxicity in rats: hippocampal expression analyses reveal the involvement of periarterial osteopontin.
    Morita M; Imai H; Liu Y; Xu X; Sadamatsu M; Nakagami R; Shirakawa T; Nakano K; Kita Y; Yoshida K; Tsunashima K; Kato N
    Neuroscience; 2008 Jun; 153(4):1135-45. PubMed ID: 18440706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice.
    Lopes CT; Gallo AP; Palma PV; Cury PM; Bueno V
    Transplant Proc; 2008 Apr; 40(3):856-60. PubMed ID: 18455036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunosuppressant calcineurin inhibitors phase shift circadian rhythms and inhibit circadian responses to light.
    Katz ME; Simonetta SH; Ralph MR; Golombek DA
    Pharmacol Biochem Behav; 2008 Oct; 90(4):763-8. PubMed ID: 18590756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunosuppressant FK506 decreases the intracellular magnesium in the human osteoblast cell by inhibiting the ERK1/2 pathway.
    Jeon SH; Kim SJ; Kim JS; Kang HS
    Life Sci; 2009 Jan; 84(1-2):23-7. PubMed ID: 19027753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination therapy with transductive anti-death FNK protein and FK506 ameliorates brain damage with focal transient ischemia in rat.
    Katsura K; Takahashi K; Asoh S; Watanabe M; Sakurazawa M; Ohsawa I; Mori T; Igarashi H; Ohkubo S; Katayama Y; Ohta S
    J Neurochem; 2008 Jul; 106(1):258-70. PubMed ID: 18363825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional drift of sequence attributes in the FK506-binding proteins (FKBPs).
    Galat A
    J Chem Inf Model; 2008 May; 48(5):1118-30. PubMed ID: 18412331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bombesin protection against FK506 neurotoxicity.
    Roesler R; Schwartsmann G; Dal Pizzol F
    J Pediatr Surg; 2007 Apr; 42(4):750; author reply 751. PubMed ID: 17448782
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.